EHA 2020 – Cross-trial comparison shows benefit of tafasitamab in patients with diffuse large B-cell lymphomas


  • Michael Simm
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • According to the primary investigator, “significant and clinically meaningful improvements” were demonstrated for the addition of tafasitamab (Tafa) to lenalidomide (LEN) by comparing patients from 2 different trials.

Why this matters

  • Patients with relapsed/refractory (R/R) diffuse large B-cell lymphomas (DLBCL) who are ineligible for transplantation have a poor prognosis and few treatment options.
  • Tafa is an anti-CD19 antibody with direct tumor cytotoxicity in clinical trials for DLBCL. 

Study design

  • RE-MIND is a global real-world data study of LEN in DLBLC. L-MIND is an ongoing, open-label, phase 2 study of Tafa+LEN. L-MIND provided a matched cohort to RE-MIND with the goal of isolating the contribution of Tafa to combination therapy.
  • 76 patients from each trial were matched for 9 baseline characteristics through electronic case records.
  • Median follow-up was approximately 21 months.
  • Funding: MorphoSys AG.

Key results

  • The primary outcome of a significantly better overall response rate (ORR) under Tafa was met: 67.1% vs 34.2%. The odd ratio of ORR was 3.9 (95% CI, 1.9-8.1; P<.0001>
  • Complete responses: 39.5% vs 13.2%.
  • Median progression-free survival: 12.1 vs 4.0 months.
  • Median overall survival: not reached vs 9.4 months.

Limitations

  • Unusual, indirect comparison of 2 different drug regimens across different trials.